{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Durham&page=21&state=North+Carolina", "query": { "state": "North Carolina", "city": "Durham", "page": 21 }, "page_size": 10 }, "pagination": { "page": 21, "page_size": 10, "total_count": 1193, "total_pages": 120, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Durham&page=22&state=North+Carolina&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Durham&page=20&state=North+Carolina&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-02T00:34:22.721Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00294541", "title": "A Study Evaluating the Long-Term Safety of ICA-17043 in Sickle Cell Disease Patients With or Without Hydroxyurea Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Sickle Cell Disease", "Sickle Cell Anemia" ], "interventions": [ { "name": "ICA-17043", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Icagen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "17 Years", "maximum_age": "66 Years", "sex": "ALL", "summary": "17 Years to 66 Years" }, "enrollment_count": 51, "start_date": "2006-02", "completion_date": "2007-06", "has_results": false, "last_update_posted_date": "2007-09-11", "last_synced_at": "2026-11-02T00:34:22.721Z", "location_count": 31, "location_summary": "Mobile, Alabama • Little Rock, Arkansas • Oakland, California + 25 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Oakland", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00294541" }, { "nct_id": "NCT00547651", "title": "AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Small Cell Lung Cancer" ], "interventions": [ { "name": "Amrubicin", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 637, "start_date": "2007-09-01", "completion_date": "2011-05-01", "has_results": false, "last_update_posted_date": "2019-11-06", "last_synced_at": "2026-11-02T00:34:22.721Z", "location_count": 61, "location_summary": "Muscle Shoals, Alabama • Tucson, Arizona • Little Rock, Arkansas + 57 more", "locations": [ { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Fresno", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00547651" }, { "nct_id": "NCT00228553", "title": "Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Excessive Daytime Sleepiness", "Narcolepsy", "Obstructive Sleep Apnea/Hypopnea Syndrome", "Chronic Shift Work Sleep Disorder" ], "interventions": [ { "name": "Armodafinil 100 to 250 mg/day", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cephalon", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 743, "start_date": "2004-05", "completion_date": "2006-07", "has_results": true, "last_update_posted_date": "2013-07-19", "last_synced_at": "2026-11-02T00:34:22.721Z", "location_count": 74, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 64 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00228553" }, { "nct_id": "NCT06901531", "title": "A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer", "Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer", "Metastatic Gastric Adenocarcinoma or Cancer", "Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma" ], "interventions": [ { "name": "zolbetuximab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Folinic acid (leucovorin or local equivalent)", "type": "DRUG" }, { "name": "5-fluorouracil (5-FU)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 500, "start_date": "2025-05-22", "completion_date": "2028-09-30", "has_results": false, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-11-02T00:34:22.721Z", "location_count": 37, "location_summary": "Birmingham, Alabama • Bakersfield, California • Cerritos, California + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Cerritos", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06901531" }, { "nct_id": "NCT03142334", "title": "Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 994, "start_date": "2017-06-09", "completion_date": "2026-02-04", "has_results": true, "last_update_posted_date": "2026-03-10", "last_synced_at": "2026-11-02T00:34:22.721Z", "location_count": 62, "location_summary": "Phoenix, Arizona • Los Angeles, California • San Francisco, California + 52 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Barbara", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03142334" }, { "nct_id": "NCT02780414", "title": "Collection of Samples From Pregnant Women for the Evaluation of Preeclampsia (Pre-E) Biomarkers", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Preeclampsia", "Hypertension", "Proteinuria", "Thrombocytopenia", "Renal Insufficiency", "Impaired Liver Function", "Pulmonary Edema" ], "interventions": [], "intervention_types": [], "sponsor": "Progenity, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 1730, "start_date": "2016-01", "completion_date": "2020-10-23", "has_results": false, "last_update_posted_date": "2022-03-11", "last_synced_at": "2026-11-02T00:34:22.721Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Aurora, Colorado • New Haven, Connecticut + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02780414" }, { "nct_id": "NCT03799432", "title": "Collaborative Organizational Approach to Selecting and Tailoring Implementation Strategies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Psychological Trauma", "Mental Health" ], "interventions": [ { "name": "COAST-IS", "type": "OTHER" }, { "name": "TF-CBT Learning Collaborative", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 62, "start_date": "2019-07-08", "completion_date": "2021-09-30", "has_results": false, "last_update_posted_date": "2022-04-27", "last_synced_at": "2026-11-02T00:34:22.721Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03799432" }, { "nct_id": "NCT00006152", "title": "A Study to See If Taking One or Two Extra Drugs Can Lower HIV Levels in Patients Who Have Failed Their Anti-HIV Drug Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Ritonavir", "type": "DRUG" }, { "name": "Abacavir sulfate", "type": "DRUG" }, { "name": "Amprenavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 42, "start_date": null, "completion_date": "2002-08", "has_results": false, "last_update_posted_date": "2021-11-01", "last_synced_at": "2026-11-02T00:34:22.721Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006152" }, { "nct_id": "NCT01696084", "title": "Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "High Risk Acute Myeloid Leukemia" ], "interventions": [ { "name": "CPX-351", "type": "DRUG" }, { "name": "7+3 (cytarabine and daunorubicin)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jazz Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "60 Years to 75 Years" }, "enrollment_count": 309, "start_date": "2012-12-13", "completion_date": "2015-12-31", "has_results": true, "last_update_posted_date": "2020-08-10", "last_synced_at": "2026-11-02T00:34:22.721Z", "location_count": 39, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 31 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01696084" }, { "nct_id": "NCT02489539", "title": "Assessment of the GORE® EXCLUDER® Conformable AAA Endoprosthesis in the Treatment of Abdominal Aortic Aneurysms", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Aortic Aneurysm, Abdominal" ], "interventions": [ { "name": "GORE® EXCLUDER® Conformable AAA Endoprosthesis", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "W.L.Gore & Associates", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 175, "start_date": "2017-12-19", "completion_date": "2027-12-31", "has_results": true, "last_update_posted_date": "2025-08-13", "last_synced_at": "2026-11-02T00:34:22.721Z", "location_count": 51, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 45 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02489539" } ] }